• Lytix Biopharma will present updated Phase II NeoLIPA results at ESMO IO in London on December 15, 2026.
• The trial met its primary endpoint, as announced November 3, 2026.
• Led by Oslo University Hospital, the study evaluates ruxotemitide with pembrolizumab before surgery in patients with resectable melanoma.
• Results will be made public on the presentation date under ESMO's embargo policy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief via NewsWeb, the disclosure sustem operated by Euronext Oslo (Ref. ID: 202611090100OSLOBORSNEWS__EN_D9829213614948CFA1A499EA652F7C5), on November 09, 2026, and is solely responsible for the information contained therein.